SEC Form 4/A · accession 0000886163-18-000100
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jason Aryeh
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jul 3, 2018 · 6:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $195.91 | Jun 19, 2018 | A | 2,474 | A | — | Jun 18, 2028 | Common Stock | 2,474 | 2,474 | D |
Explanation of responses
- F1This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date.
- F2Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.